Clinical Trial Update: A Study to Evaluate the Effects of Indacaterol Maleate (QAB149) as a New Formulation in the EPIC Test Fixture [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a new formulation of indacaterol maleate (QAB149) for asthma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Indacaterol Maleate (QAB149) (indacaterol maleate)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Asthma | Phase 2 | Status: WITHDRAWN